Further bioinformatic analysis revealed that despite being associated with chemoresistant disease, AREG mRNA levels were significantly (p < 0.05) higher in patients with a higher mutation count and tumor mutational burden (TMB), when stratified by quartile (Figures 1B, C). This evidence concerns the gene AREG and neoplasm.